Thioctic Acid

Phase 3Small molecule

MMEDA Pharma GmbH & Co. KG

Thioctic Acid is one of 170 small molecule programs targeting Diabetic Nephropathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

169

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetic NephropathyActive, not recruiting

MyopathyActive, not recruiting

Diabetic PolyneuropathyActive, not recruiting

DementiaActive, not recruiting

Diabetic NeuropathyActive, not recruiting

Diabetic NephropathyPhase 3

Active, not recruiting

MyopathyPreclinical

Active, not recruiting

Diabetic PolyneuropathyPhase 3

Active, not recruiting

DementiaPhase 2

Active, not recruiting

Diabetic NeuropathyPhase 3

Active, not recruiting

Competition

Competitive Landscape

138 competitors in Dementia

#DrugCompanyPhaseTrials

Leqembi

Eisai

Phase 3

2 2

Depacon

AbbVie

Phase 3

1 3

Abilify

Otsuka

Phase 3

1 4

MS Contin

HHikma Pharmaceuticals LLC

Phase 3

1 5

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 6

Glucophage

EMD Serono

Phase 3

1 7

Aricept

Eisai

Phase 3

2 8

Seroquel

AstraZeneca

Phase 3

1 9

Vesicare

Astellas

Phase 2

1 10

Aleve

Alnylam Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Diabetic Polyneuropathy1 trial

Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2)

Completed·MMEDA Pharma GmbH & Co. KG·Phase 3·NCT00977483·460 enrolled

Diabetic Nephropathy1 trial

Alpha-lipoic Acid in Diabetic Nephropathy

Unknown status·—·Phase 3·NCT06253429·30 enrolled

Diabetic Neuropathy1 trial

Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2)

Completed·MMEDA Pharma GmbH & Co. KG·Phase 3·NCT00328601·170 enrolled

Dementia1 trial

A Study of Thioctic Acid and Deprenyl in HIV-Infected Patients With Dementia

Completed·TThe Dana Foundation·Phase 2·NCT00002154·32 enrolled

Myopathy1 trial

Pilot Compassionate Use Study of Thioctic Acid Treatment in Mitochondrial Myopathy

Completed·NNational Center for Research Resources (NCRR)·N/A·NCT00004770·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Thioctic Acid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Thioctic Acid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Thioctic Acid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — MEDA Pharma GmbH & Co. KG company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMEDA Pharma GmbH & Co. KG

Thioctic Acid

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Diabetic Polyneuropathy1 trial

Diabetic Nephropathy1 trial

Diabetic Neuropathy1 trial

Dementia1 trial

Myopathy1 trial

References

Drug Info

Quick Facts

Related News